尼莫地平联合奥拉西坦治疗急性脑出血的临床研究
Clinical Study on Nimodipine Combined with Oxiracetam in the Treatment of Acute Cerebral Hemorrhage
王绍菲 1彭艳丽 1田甜1
作者信息
- 1. 平顶山市第二人民医院急诊科,河南平顶山 467000
- 折叠
摘要
目的 探讨尼莫地平联合奥拉西坦治疗急性脑出血患者的临床效果及对其氧化应激反应的影响.方法 将86例急性脑出血患者随机分为观察组(n=43)和对照组(n=43).对照组采用尼莫地平治疗,观察组采用尼莫地平联合奥拉西坦治疗,均持续治疗15 d.比较两组的临床疗效、氧化应激反应及不良反应发生率.结果 观察组治疗总有效率为95.35％,高于对照组的72.09％(P＜0.05).治疗后,观察组血清超氧化物歧化酶(SOD)水平高于对照组,血浆丙二醛(MDA)水平低于对照组(P＜0.05).治疗期间,观察组不良反应发生率为9.30％,与对照组的11.63％比较无统计学差异(P＞0.05).结论 尼莫地平联合奥拉西坦治疗急性脑出血效果显著,可明显减轻患者机体氧化应激反应,且安全可靠,值得临床推广应用.
Abstract
Objective To explore the clinical efficacy of nimodipine combined with oxiracetam in the treatment of patients with acute cerebral hemorrhage and the impact on the oxidative stress response.Methods 86 patients with acute cerebral hemorrhage were randomly divided into observation group(n=43)and control group(n=43).The control group was treated with nimodipine,and the observation group was treated with nimodipine combined with oxiracetam.Both groups were treated for 15 days.The clinical efficacy,oxidative stress response and the incidence of adverse reactions were compared.Results The total effective rate of treatment in the observation group 95.35％,higher than 72.09％ in the control group(P＜0.05).After treatment,the serum superoxide dismutase(SOD)level of the observation group was higher than that of the control group,and the plasma malondialdehyde(MDA)level was lower than that of the control group(P＜0.05).During the treatment,no statistical difference was found in the incidence of adverse reactions(9.30％ vs.11.63％)between the two groups(P＞0.05).Conclusions Nimodipine combined with oxiracetam has significant treatment effect in the treatment of acute cerebral hemorrhage,can significantly reduce the patients'oxidative stress response,and is safe and reliable,which is worthy of clinical promotion and application.
关键词
急性脑出血/尼莫地平/奥拉西坦/治疗效果/氧化应激反应Key words
Acute cerebral hemorrhage/Nimodipine/Oxiracetam/Treatment effect/Oxidative stress response引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据